Charles River Laboratories consensus steadies, shares trade in a crowded life-science field

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-30, 13:41.

Charles River Laboratories (US1591881009) sits on the NASDAQ with a dense analyst coverage that shapes expectations for its next earnings release. Wall Street houses have refreshed views on the stock in recent months, giving retail investors a clearer picture of how the company is positioned versus other U.S. health-care names.

What recent analyst notes signal

Several brokers have updated their stance on Charles River Laboratories in the run-up to its quarterly numbers, with U.S. firms such as Morgan Stanley and regional Asia-focused houses mentioned in secondary coverage as adjusting ratings and price targets around the spring earnings season. One recent summary noted Morgan Stanley upgrading Charles River to Overweight from Equal Weight and lifting the price target to 220 dollars from 185 dollars, and CLSA moving to Outperform with a target of 219 dollars from 167 dollars, signaling a more constructive view on the company’s earnings power and contract research momentum.

The NASDAQ listing places Charles River in a peer group that includes large-cap health-care and life-science tools names such as Thermo Fisher Scientific, Danaher and IQVIA, where analyst coverage is typically intense and valuation multiples are watched closely. Retail investors tracking the sector often use consensus data across these peers to compare forward price-to-earnings ratios, free cash flow yields and expected revenue growth, with Charles River Laboratories evaluated against similar contract research organizations and laboratory service providers.

Consensus estimates and sector context

According to aggregated sell-side data from common financial platforms, Charles River Laboratories typically screens as a mid-to-large-cap health-care name with a mix of Buy, Hold and Sell recommendations, and a 12-month price target spread reflecting differing views on growth in preclinical services, biologics testing and safety assessment work. The consensus picture for NASDAQ-listed health-care equipment and services stocks in mid-2026 shows a moderate-bias toward Buy ratings across the group, with risk flagged around pricing, regulatory scrutiny and funding cycles in biotech and pharma, factors that also affect Charles River’s pipeline of outsourced projects.

Peer comparisons in the sector highlight that contract research players like Icon, Labcorp and IQVIA often trade at high-teens to low-twenties forward earnings multiples when growth and margin expansion are perceived as robust. Charles River Laboratories is usually assessed within that band, with analysts looking at its book of long-term contracts, exposure to large biopharma clients, and potential leverage from specialized niches such as cell and gene therapy-related testing and research models.

The business behind the stock

Charles River Laboratories generates its revenue by providing laboratory-based services and products to pharmaceutical, biotechnology and other life-science clients worldwide. The company is widely known for its preclinical contract research services, including toxicology studies, safety assessments and efficacy testing that support early-stage drug development. A representative offering is its provision of laboratory animals and customized research models for experimental work, alongside associated services such as breeding, genetic characterization and health monitoring.

Where the stock trades today

Charles River Laboratories shares (US1591881009) trade on the NASDAQ in U.S. dollars as of 2026-06-30, 13:41. Intraday price data and market capitalization figures for the stock are available on major quote platforms and the NASDAQ website, reflecting live trading conditions during the New York session.

Disclaimer: This text is for informational purposes only and does not constitute investment advice, a securities recommendation or an offer to buy or sell financial instruments. All data were compiled with care but without guarantee; investors should consult official filings, the company’s investor relations materials and independent financial advisers before making investment decisions.